Who are the key players in North America Non Invasive Prenatal Testing Market industry?

The leading players in the North America Non-Invasive Prenatal Testing (NIPT) market include Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics, and F. Hoffmann-La Roche AG. These companies focus on innovative genetic screening technology, expanding test portfolios, and strategic collaborations to maintain a competitive edge.

Which segment accounted for the largest North America Non Invasive Prenatal Testing Market share?

The trisomy screening segment, especially for detection of chromosomal abnormalities like Down syndrome (trisomy 21), holds the largest market share in North America. High accuracy, early detection capabilities, and strong recommendations by healthcare providers have contributed to the dominance of this application over other test indications.

What are the factors driving the North America Non Invasive Prenatal Testing Market?

Key drivers include increasing maternal age, favorable reimbursement policies, and continuous technological advancements. For example, Natera’s launch of Panorama AI, which leverages artificial intelligence to improve test accuracy, exemplifies innovation accelerating market expansion and boosting healthcare provider confidence.

Which type accounted for the largest North America Non Invasive Prenatal Testing Market share?

Cell-free DNA (cfDNA) based NIPT tests capture the largest market share in North America. Their non-invasiveness, high sensitivity, and specificity for detecting chromosomal aneuploidies have made them the preferred choice among clinicians and expectant mothers, outpacing traditional screening approaches.

Home Healthcare

North America Non Invasive Prenatal Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Q: What is the North America Non Invasive Prenatal Testing Market growth?

The North America NIPT market is experiencing robust growth, driven by technological advancements and increasing patient awareness. In 2023, Illumina reported significant revenue growth in its prenatal testing segment, mainly fueled by broader adoption and insurance coverage for cell-free DNA-based screening tests across the United States and Canada.

North America Non Invasive Prenatal Testing Market: by Type (Ultrasound, Cell-free Fetal DNA (cffDNA), Fetal Nucleated Red Blood Cells (fnRBCs), Methylated DNA Markers, Others), Application (Trisomy, Microdeletion Syndrome, Monosomy, Sex Chromosome Aneuploidies, Others), Distribution Channels (Hospitals, Clinical Laboratories, Diagnostic Centers, Physician Offices, Online, Others), Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Rolling Circular Amplification, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20417

Market Segmentation

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1800
Regions	United States, Canada, Mexico
Segments	Type: Ultrasound, Cell-free Fetal DNA (cffDNA), Fetal Nucleated Red Blood Cells (fnRBCs), Methylated DNA Markers, Others; Application: Trisomy, Microdeletion Syndrome, Monosomy, Sex Chromosome Aneuploidies, Others; Distribution Channels: Hospitals, Clinical Laboratories, Diagnostic Centers, Physician Offices, Online, Others; Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Rolling Circular Amplification, Others; Organization Size: Small, Medium, Large
Players	Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Eurofins Scientific, PerkinElmer, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., GE Healthcare, Koninklijke Philips N.V., Yourgene Health plc, Safeguard DNA Diagnostic, Inc., Progenity, Inc.

Frequently asked questions

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Study period:

2020-2035

Base year:

2026

Historical data

2020-2024

NO OF PAGE:

167

Customize This Report to Suit Your Requirements

Name

Bussiness Email

country

Phone number

Consulting Service

How Will You Befit From our consulting service

Get in touch with Us

US +91 89837 31618 (Tool Free)

sales [at] bussinessinsights.com

Market Segmentation

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	1800
Regions	United States, Canada, Mexico
Segments	Type: Ultrasound, Cell-free Fetal DNA (cffDNA), Fetal Nucleated Red Blood Cells (fnRBCs), Methylated DNA Markers, Others; Application: Trisomy, Microdeletion Syndrome, Monosomy, Sex Chromosome Aneuploidies, Others; Distribution Channels: Hospitals, Clinical Laboratories, Diagnostic Centers, Physician Offices, Online, Others; Technology: Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, Rolling Circular Amplification, Others; Organization Size: Small, Medium, Large
Players	Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Eurofins Scientific, PerkinElmer, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., GE Healthcare, Koninklijke Philips N.V., Yourgene Health plc, Safeguard DNA Diagnostic, Inc., Progenity, Inc.